Cytokinetics Announces Opening of COSMIC-HF, A Phase II Clinical Trial of Oral Formulations of Omecamtiv Mecarbil in Patients with Heart Failure

[at noodls] – South San Francisco, CA – February 12, 2013 Cytokinetics, Incorporated (Nasdaq: CYTK) announced today the opening to enrollment of a Phase II clinical trial of oral formulations of omecamtiv mecarbil. … more

View todays social media effects on CYTK

View the latest stocks trending across Twitter. Click to view dashboard

See who Cytokinetics is hiring next, click here to view